104 related articles for article (PubMed ID: 9052751)
1. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
Schaer JC; Waser B; Mengod G; Reubi JC
Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
[TBL] [Abstract][Full Text] [Related]
2. Molecular evidence and clinical importance of β-arrestins expression in patients with acromegaly.
Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Chimelli L; Luque RM; Kasuki L; Gadelha MR
J Cell Mol Med; 2018 Apr; 22(4):2110-2116. PubMed ID: 29377493
[TBL] [Abstract][Full Text] [Related]
3. Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach.
Oron-Herman M; Kirmayer D; Lupp A; Schulz S; Kostenich G; Afargan M
Sci Rep; 2023 Nov; 13(1):20857. PubMed ID: 38012197
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.
Cakir M; Dworakowska D; Grossman A
J Cell Mol Med; 2010 Nov; 14(11):2585-91. PubMed ID: 20629988
[No Abstract] [Full Text] [Related]
5. Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas.
Kaemmerer D; Sänger J; Arsenic R; D'Haese JG; Neumann J; Schmitt-Graeff A; Wirtz RM; Schulz S; Lupp A
Oncotarget; 2017 Oct; 8(52):89958-89969. PubMed ID: 29163802
[TBL] [Abstract][Full Text] [Related]
6. The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review.
Kasprzak A; Geltz A
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540191
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptors and the associated intracellular machinery: the two sides of the coin.
Campana C; Iyer AM; Ferone D; Gatto F; Hofland LJ
J Endocrinol; 2024 Mar; 260(3):. PubMed ID: 38224333
[TBL] [Abstract][Full Text] [Related]
8. Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [
Tatsi A; Maina T; Waser B; Krenning EP; de Jong M; Reubi JC; Cordopatis P; Nock BA
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339198
[TBL] [Abstract][Full Text] [Related]
9. Highlighting Fibroblasts Activation in Fibrosis: The State-of-The-Art Fibroblast Activation Protein Inhibitor PET Imaging in Cardiovascular Diseases.
Cui Y; Wang Y; Wang S; Du B; Li X; Li Y
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762974
[TBL] [Abstract][Full Text] [Related]
10.
Rubira L; Deshayes E; Santoro L; Kotzki PO; Fersing C
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111537
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of primary neuroendocrine breast cancer: A population-based study.
Ma ST; Wang DY; Liu YB; Tan HJ; Ge YY; Chi Y; Zhang BL
Cancer Med; 2022 Jul; 11(13):2533-2540. PubMed ID: 35499193
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin and Its Receptor System in Colorectal Cancer.
Kasprzak A
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829972
[TBL] [Abstract][Full Text] [Related]
13. Peptide-Based Strategies for Targeted Tumor Treatment and Imaging.
Ayo A; Laakkonen P
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33918106
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography.
Dude I; Zhang Z; Rousseau J; Hundal-Jabal N; Colpo N; Merkens H; Lin KS; Bénard F
EJNMMI Radiopharm Chem; 2017; 2(1):4. PubMed ID: 29503845
[TBL] [Abstract][Full Text] [Related]
15. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.
Ben-Shlomo A; Liu NA; Melmed S
Pituitary; 2017 Feb; 20(1):93-99. PubMed ID: 27900635
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy in pancreatic cancer.
Liu SX; Xia ZS; Zhong YQ
World J Gastroenterol; 2014 Oct; 20(37):13343-68. PubMed ID: 25309069
[TBL] [Abstract][Full Text] [Related]
19. Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation.
Savelli G; Zaniboni A; Bertagna F; Bosio G; Nisa L; Rodella C; Biasiotto G; Bettinsoli G; Migliorati E; Peli A; Falchi R; Giuffrida F; Giubbini R
Breast Care (Basel); 2012 Oct; 7(5):408-10. PubMed ID: 24647781
[TBL] [Abstract][Full Text] [Related]
20. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study.
Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
EJNMMI Res; 2012 Jun; 2(1):25. PubMed ID: 22682002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
